Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:48 2026-07-17 am EDT			5-day change	1st Jan Change
125.00 ^CHF	+1.41%		+0.58%	+14.05%

Jul. 17	Swiss Market Index Ends Week Upbeat; Georg Fischer Climbs	MT
Jul. 17	AI's Blank Check Is Bouncing

Novartis RemIND data at EAACI show Rhapsido(R) potential as first targeted therapy for chronic inducible urticaria (CIndU)

Published on 06/12/2026 at 05:36 am EDT

Dow Jones

Add MarketScreener to your sources

NOVARTIS AG

+1.41%

(MORE TO FOLLOW) Dow Jones Newswires

June 12, 2026 05:36 ET (09:36 GMT)

Add MarketScreener to your sources

Latest news about Novartis AG

Jul. 17	Swiss Market Index Ends Week Upbeat; Georg Fischer Climbs	MT
Jul. 17	AI's Blank Check Is Bouncing
Jul. 17	NOVARTIS AG : Deutsche Bank keeps its Buy rating	ZD
Jul. 17	Novartis' Fabhalta Receives FDA Traditional Approval for Primary IgA Nephropathy	MT
Jul. 17	A Tough Week for the Market's Favourite Stocks
Jul. 17	Novartis receives traditional approval in IgAN
Jul. 17	Novartis Receives FDA Traditional Approval for Fabhalta to Slow Kidney Function Decline in Primary IgAN	CI
Jul. 17	Swiss stocks - Factors to watch on July 17	RE
Jul. 16	Novartis Obtains US FDA's Traditional Approval for Kidney Disease Drug Fabhalta	MT
Jul. 16	Novartis Fabhalta(R) (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN	DJ
Jul. 16	European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday	MT
Jul. 16	European earnings growth seen strongest in 3 years as energy profits surge	RE
Jul. 16	Europe Inc heads into strongest earnings season in years, but AI gap persists	RE
Jul. 14	US FDA approves Celcuity's breast cancer drug	RE
Jul. 14	Where would AI lead Pharma in the long run?

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company